NATURAL HOLISTIC MEDICINE BLOG - Jim Cramer has officially pivoted his stance on Novo Nordisk (NYSE:NVO) following the company's robust Q2 2026 earnings report. This notable change of heart occurred during the August 12 episode of Mad Money, where the market analyst addressed the recent volatility surrounding the Danish pharmaceutical giant.
A Shift in Market Sentiment
The stock experienced sharp fluctuations following the release of the quarterly results, prompting Cramer to highlight the disconnect between the company's fundamental performance and the initial negative market reaction. Cramer remarked that while the stock fell nearly 6% on the day the numbers were released, it quickly reclaimed most of its losses, proving that Wall Street’s knee-jerk reaction may have been premature.
Cramer’s recent praise represents a distinct departure from his more cautious outlook earlier in the year. On January 29, he expressed a preference for the trajectory of Eli Lilly, famously stating that he viewed Novo Nordisk as a hold rather than a buy. By April 27, his stance had turned even more bearish, with concerns that Novo Nordisk would lose critical market share in the pill segment to its primary competitor, Eli Lilly.
Q2 2026 Performance and Financial Growth
The reality of Novo Nordisk's Q2 2026 results and the successful rollout of its oral Wegovy formulation have significantly challenged the original bearish thesis. The company delivered impressive net sales of DKK 78.49 billion, which translates to approximately $12.1 billion, representing 7% growth at constant exchange rates on an adjusted basis.
Profitability metrics also signaled underlying operational strength for the drug manufacturer. Adjusted operating profit grew by 11% at constant exchange rates, reaching DKK 33.39 billion for the quarter. These figures underscore the company's ability to navigate competitive pressures while maintaining solid margins in a challenging economic environment.
The Success of the Oral Wegovy Pill
The primary driver behind this outperformance is the rapid adoption of the oral Wegovy pill, which has exceeded market expectations. Since its early-2026 launch, the pill has already surpassed 5 million total prescriptions, indicating a strong demand that extends beyond patients previously committed to injectable treatments.
This oral formulation is successfully capturing a new segment of the patient population that historically resisted the need for injections. By simplifying the administration of the GLP-1 treatment, Novo Nordisk has tapped into a vast market that was previously underserved or unwilling to use traditional delivery methods.
Wall Street's Mixed Reaction
Despite the raised guidance and solid performance, several sell-side analysts remain cautious regarding the near-term upside potential. On August 6, BMO Capital analyst Evan Seigerman reiterated a Market Perform rating while modestly raising his price target from $45 to $47. Seigerman acknowledged the traction of the Wegovy pill but noted that overall results still fell slightly short of the increasingly elevated expectations from investors.
Berenberg provided a more critical assessment, downgrading the stock from Buy to Hold and trimming its Copenhagen target from DKK 325 to DKK 305. The firm argued that the easy valuation gains associated with the initial rollout have likely materialized, suggesting that future growth will require proof of sustained defense in the oral obesity market.
Institutional Backing and Future Outlook
Data tracked across major financial institutions reveals that steady institutional backing remains a cornerstone for Novo Nordisk. At the close of Q1 2026, 55 hedge funds held positions in the company, a figure that has remained relatively stable compared to the prior quarter.
Fisher Asset Management remains the company's most prominent shareholder, despite gradually trimming its position over several recent quarters. Furthermore, short interest currently sits at a low 0.93% of the float, suggesting that there is minimal speculative betting on a significant downside for the stock.
Novo Nordisk remains firmly positioned at the center of the global metabolic treatment landscape. While Jim Cramer previously urged caution in favor of Eli Lilly, the company's Q2 execution and the rapid adoption of its oral product have prompted a necessary reassessment of the stock's long-term investment thesis.
Frequently Asked Questions (FAQ)
Why did Jim Cramer change his mind about Novo Nordisk (NVO)?
Jim Cramer shifted his stance after reviewing Novo Nordisk's Q2 2026 earnings, which showed strong financial performance and high adoption rates of the oral Wegovy pill, despite his earlier concerns about competition from Eli Lilly.
How many prescriptions has the oral Wegovy pill received since its launch?
Since its launch in early 2026, the oral Wegovy pill has already surpassed 5 million total prescriptions.
What were the financial results for Novo Nordisk in Q2 2026?
Novo Nordisk reported net sales of DKK 78.49 billion (approx. $12.1 billion) and an adjusted operating profit of DKK 33.39 billion, marking an 11% growth at constant exchange rates.
What is the current analyst sentiment regarding Novo Nordisk stock?
Sentiment remains mixed. While some analysts see the pill's growth as a positive, others like Berenberg have downgraded the stock to 'Hold' due to concerns about valuations and the need for further evidence of sustained market share defense.
Comments